Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4516 Target Snapshot

Serine/threonine-protein kinase MRCK alpha · SINGLE PROTEIN · Homo sapiens

1,941Compounds
212Assays
3Approved Drugs
1,276.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q5VT25. Use UniProt Q5VT25 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q5VT25 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase MRCK alpha as ChEMBL target CHEMBL4516, mapped to UniProt Q5VT25. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase MRCK alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4516
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q5VT25
Serine/threonine-protein kinase MRCK alpha
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase MRCK alpha is the right protein anchor across sources, using UniProt Q5VT25 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase MRCK alpha
UniProt AccessionQ5VT25
Component TypeProtein
Sequence Length1732 aa

Serine/threonine-protein kinase MRCK alpha

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase MRCK alpha, mapped to UniProt Q5VT25. Sequence length is 1732 aa.

Mapped IDQ5VT25
Review nameSerine/threonine-protein kinase MRCK alpha
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

3
Approved
2
Phase III
7
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC5068.0
KI846.0
KD362.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5811574 10.92 Ki 0.012 Preclinical
CHEMBL5764454 10.85 Ki 0.014 Preclinical
CHEMBL6014969 10.82 Ki 0.015 Preclinical
CHEMBL5963387 10.72 Ki 0.019 Preclinical
CHEMBL5742314 10.68 Ki 0.021 Preclinical
CHEMBL5871406 10.55 Ki 0.028 Preclinical
CHEMBL5946285 10.55 Ki 0.028 Preclinical
CHEMBL5927623 10.49 Ki 0.032 Preclinical
CHEMBL5834378 10.48 Ki 0.033 Preclinical
CHEMBL5861512 10.39 Ki 0.041 Preclinical
Distribution

pChEMBL Value Distribution

113
5.0
59
5.5
38
6.0
35
6.5
25
7.0
19
7.5
18
8.0
10
8.5
13
9.0
15
9.5
pChEMBL
Assay Landscape

Assay Landscape

212
Total Assays
214
Tested Compounds
2
Assay Types
Binding — 211 assays, 133 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 176 121 7.9
assay format 28 5 5.8
cell-based format 6 2 7.5
subcellular format 1 5 6.3
Functional — 1 assays, 214 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 214 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine